S&CO Inc. Boosts Holdings in Eli Lilly and Company $LLY

S&CO Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 6.5% in the 1st quarter, Holdings Channel reports. The firm owned 21,519 shares of the company’s stock after buying an additional 1,310 shares during the quarter. Eli Lilly and Company accounts for 1.2% of S&CO Inc.’s holdings, making the stock its 23rd largest position. S&CO Inc.’s holdings in Eli Lilly and Company were worth $19,792,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company during the fourth quarter worth about $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LLY. Rothschild & Co Redburn lifted their price target on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Sanford C. Bernstein boosted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
• Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
• Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
• Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Eli Lilly and Company Trading Up 0.8%

Shares of LLY stock opened at $1,178.01 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business has a 50-day moving average price of $1,118.87 and a two-hundred day moving average price of $1,036.80. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The firm has a market cap of $1.11 trillion, a P/E ratio of 41.85, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 34.55 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.